Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab for Autoimmune Inner Ear Disease
NCT01526174Phase 2Terminated
- Sponsor
- House Institute Foundation
- Start
- Mar 2012
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of golimumab in autoimmune inner ear disease (AIED) (2 arms), sponsored by House Institute Foundation. Primary endpoints: Serious Adverse Events at 30 days and Pure-tone threshold change at 6 weeks. Started Mar 2012; status: terminated.
02
Drugs
golimumab
03
Conditions
autoimmune inner ear disease (AIED)
Beyond the preview
Go deeper on NCT01526174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01526174.